Titles and Affiliations

Co-Director of Breast Pathology
Massachusetts General Hospital
Professor of Pathology, Harvard Medical School
Boston, MA

Research area

Discovering new strategies to treat estrogen receptor (ER)-positive breast cancer. 

Impact

Metastatic breast cancer (MBC) is the second leading cause of cancer related death among women worldwide. Over the past decade we have witnessed substantial progress in our understanding of the genetics of MBC. However, despite this progress and despite recent advances in therapy following surgery, it is estimated that 20-30 precent of early-stage breast cancer patients go on to develop metastatic disease. Currently, there are limited therapeutic options for MBC patients who have been previously treated with standard therapy after surgery. Dr. Sgroi is working to meet the substantial need to identify additional therapeutic targets for women with MBC.

What’s next

Dr. Sgroi will use a highly innovative protein-based approach to identify abnormal biological pathways and to identify novel therapeutic targets in MBC. As this novel approach has been shown to predict drug responses in cancer models, his research holds the promise to identify novel treatment strategies for patients with MBC. 

Biography

Dr. Dennis C. Sgroi is a Professor of Pathology, Harvard Medical School, and Co-Director of Breast Pathology and Member of the Center for Cancer Research at Massachusetts General Hospital.  He maintains an active clinical practice on the breast pathology consultation service and he is actively engaged in translational research. He has served on the scientific advisory board for the Barnett Institute at Northeastern University and currently serves on the scientific advisory board for the Ontario Institute for Cancer Research. 

The overarching goals of research in the Sgroi laboratory are to develop better ways to identify patients who are at risk for the development of breast cancer and to identify those breast cancer patients who are likely to benefit from targeted drug therapies. His laboratory is taking several different approaches to achieving these goals. First, they are deciphering specific molecular events that occur during the earliest stages of tumor development and using this knowledge to develop biomarkers that will predict for increased risk of progression to cancer. Second, using advance molecular technologies, they are searching for novel breast cancer biomarkers to identify patients with hormone-receptor-positive breast cancer who are most likely to benefit from extended hormonal therapy and from novel targeted therapeutics.

BCRF Investigator Since

2015

Areas of Focus